Recombinant-DNA-derived insulin analogues as potentially useful therapeutic agents
- 1 July 1993
- journal article
- review article
- Published by Elsevier in Trends in Biotechnology
- Vol. 11 (7) , 301-305
- https://doi.org/10.1016/0167-7799(93)90018-5
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Double-blind crossover comparison of human and porcine insulins in patients reporting lack of hypoglycaemia awarenessThe Lancet, 1992
- Absorption Kinetics and Action Profiles of Subcutaneously Administered Insulin Analogues (AspB9GluB27, AspB10, AspB28) in Healthy SubjectsDiabetes Care, 1991
- Comparison of Subcutaneous Soluble Human Insulin and Insulin Analogues (AspB9, GluB27; AspB10; AspB28) on Meal-Related Plasma Glucose Excursions in Type I Diabetic SubjectsDiabetes Care, 1991
- Monomeric Insulins and Their Experimental and Clinical ImplicationsDiabetes Care, 1990
- Insulin.BMJ, 1990
- Recombinant DNA derived monomeric insulin analogue: comparison with soluble human insulin in normal subjects.BMJ, 1988
- Monomeric insulins obtained by protein engineering and their medical implicationsNature, 1988
- Bacterial Production of Human InsulinDiabetes Care, 1981
- “Normal” Insulin Secretion: The Goal of Artificial Insulin Delivery Systems?Diabetes Care, 1980
- Semi-synthesis of human insulin by trypsin-catalysed replacement of Ala-B30 by Thr in porcine insulinNature, 1979